Diagnostic performance of [18F]FAPI-04 PET/CT in suspected recurrent hepatocellular carcinoma: prospective comparison with contrast-enhanced CT/MRI
European Journal of Nuclear Medicine and Molecular Imaging · 2025
DOI: 10.1007/s00259-025-07273-4 ↗Kurz gefasst
Klinische Studie in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2025. Verfasst von Jiucen Liang und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Guangzhou Institute of Cancer Research, the Affiliated Cancer Hospital, Guangzhou Medical University, 78 Hengzhigang …. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Contrast Media, Liver Neoplasms, Magnetic Resonance Imaging. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Guangzhou Institute of Cancer Research, the Affiliated Cancer Hospital, Guangzhou Medical University Clinical Research 5555 Program, Guangdong Basic and Applied Basic Research Foundation.
Abstract (Originalsprache)
PURPOSE: To evaluate the diagnostic performance of [18F]FAPI-04 PET/CT in differentiating hepatocellular carcinoma (HCC) recurrence from treatment-induced lesions (TILs) after therapy and compare it with contrast-enhanced CT/MRI (Ce-CT/MRI). METHODS: Patients with suspected HCC recurrence after resection or local-regional therapy, who underwent Ce-CT/MRI and [18F]FAPI-04 PET/CT, were prospectively enrolled. For each patient or lesion, a three-point-scale (positive, negative, or equivocal) was assigned to Ce-CT/MRI and [18F]FAPI-04 PET/CT. The diagnostic performances of Ce-CT/MRI, [18F]FAPI-04 PET/CT, and their combination were compared by McNemar's test, with histopathology or radiographic follow-up as a reference standard. The maximum standardized uptake value (SUVmax) and lesion-to-background ratio (LBR) of lesions derived from [18F]FAPI-04 PET/CT were analyzed, and the cut-off points for distinguishing between HCC recurrence and TILs were calculated. RESULTS: A total of 44 patients with 129 lesions were analyzed, of which 31 patients (91 lesions) were proved to be recurrent HCC and 38 lesions were TILs. On lesion-based analysis, the combination of [18F]FAPI-04 PET/CT with Ce-CT/MRI demonstrated superior sensitivity (86.8% vs. 70.3% vs. 72.5%), specificity (89.5% vs. 42.1% vs. 52.6%), and accuracy (87.6% vs. 62.0% vs. 66.7%) compared to Ce-CT/MRI and [18F]FAPI-04 PET/CT alone (all P < 0.001). The combination altered therapy management in 22.7% of patients. On semiquantitative analysis, the SUVmax and LBR of [18F]FAPI-04 PET in HCC recurrence (n = 91) were significantly higher than those in TILs (n = 38) (SUVmax: 8.1 vs. 3.65, P < 0.001; LBR: 5.4 vs. 1.9, P < 0.001). Using cutoff points of 5.1 for SUVmax and 2.3 for LBR, [18F]FAPI-04 PET/CT exhibited high sensitivity and specificity in differentiating recurrent HCC from TILs, with 83.5%, 78.9% and 96.2%, 63.2%, respectively. CONCLUSIONS: The combination of [18F]FAPI-04 PET/CT with Ce-CT/MRI significantly improved diagnostic sensitivity, specificity, and accuracy in differentiating recurrent HCC from TILs. [18F]FAPI-04 PET may be a promising imaging modality in detecting recurrent HCC. TRIAL REGISTRATION: clinicaltrials.gov: NCT05485792.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, Guangzhou Institute of Cancer Research, the Affiliated Cancer Hospital, Guangzhou Medical University, 78 Hengzhigang Road, Guangzhou, Guangdong, 510095, P. R. China.
- Department of Institute of Cancer Research, Guangzhou Institute of Cancer Research, the Affiliated Cancer Hospital, Guangzhou Medical University, 78 Hengzhigang Road, Guangzhou, Guangdong, 510095, P. R. China.
- Department of Radiology and Imaging Sciences, Emory University, Atlanta, GA, 30322, USA.
- Department of Nuclear Medicine, Guangzhou Institute of Cancer Research, the Affiliated Cancer Hospital, Guangzhou Medical University, 78 Hengzhigang Road, Guangzhou, Guangdong, 510095, P. R. China. zhangrusen2015@163.co…
- Department of Radiology and Imaging Sciences, Emory University, Atlanta, GA, 30322, USA. steven.liang@emory.edu.
- Department of Nuclear Medicine, Guangzhou Institute of Cancer Research, the Affiliated Cancer Hospital, Guangzhou Medical University, 78 Hengzhigang Road, Guangzhou, Guangdong, 510095, P. R. China. zhanglinqi0909@163.co…
ORCID-Profile: Linqi Zhang
Förderung
- National Natural Science Foundation of China
- Guangzhou Institute of Cancer Research, the Affiliated Cancer Hospital, Guangzhou Medical University Clinical Research 5555 Program
- Guangdong Basic and Applied Basic Research Foundation
Zitieren
APA
Liang, J., Weng, S., Zhang, J., Jiang, S., Li, W., Li, S., Rong, J., Liu, H., Chen, H., Liu, Z., Peng, H., Yan, S., Zhang, R., Liang, S. H., & Zhang, L. (2025). Diagnostic performance of [18F]FAPI-04 PET/CT in suspected recurrent hepatocellular carcinoma: prospective comparison with contrast-enhanced CT/MRI. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-025-07273-4
Vancouver
Liang J, Weng S, Zhang J, Jiang S, Li W, Li S, et al. Diagnostic performance of [18F]FAPI-04 PET/CT in suspected recurrent hepatocellular carcinoma: prospective comparison with contrast-enhanced CT/MRI. European Journal of Nuclear Medicine and Molecular Imaging. 2025. doi:10.1007/s00259-025-07273-4
BibTeX
@article{Liang2025,
author = {Liang, Jiucen and Weng, Shaojuan and Zhang, Jing and Jiang, Shuqin and Li, Wen and Li, Shuyi and Rong, Jian and Liu, Hao and Chen, Haipeng and Liu, Zhidong and Peng, Hao and Yan, Sha and Zhang, Rusen and Liang, Steven H and Zhang, Linqi},
title = {Diagnostic performance of [18F]FAPI-04 PET/CT in suspected recurrent hepatocellular carcinoma: prospective comparison with contrast-enhanced CT/MRI},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2025},
doi = {10.1007/s00259-025-07273-4}
}
EUVIMED